GSK plc (the 'Company')
Transaction notification
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Hal Barron |
|||
| b) |
Position/status |
Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$47.1800 |
2,732.837 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-11-14 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Hal Barron |
|||
| b) |
Position/status |
Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$47.1800 |
69 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-11-14 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
James Ford |
|||
| b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$47.1800 |
50.851 |
|
||
| |
|
|
|
||
| d) |
Aggregated information |
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-11-14 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG